Platelet aggregation for diagnosing acute kidney transplant rejection
Platelet Aggregation in the Diagnosis of Acute Graft Rejection
This study will test whether changes in platelet activation measured from blood can help detect acute rejection in adult kidney transplant recipients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Martin Academic / other |
| Locations | 1 site (Martin) |
| Trial ID | NCT07275541 on ClinicalTrials.gov |
What this trial studies
This pilot observational study longitudinally measures platelet aggregation and activation markers in adult kidney transplant recipients before transplant and at protocol biopsies 3 and 12 months after transplant, and in patients undergoing indication biopsies for suspected graft dysfunction. Platelet function is measured by optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels. These platelet parameters are correlated with biopsy histology, donor-specific antibodies, metabolic data, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify cellular or antibody-mediated rejection and support development of a non-invasive diagnostic tool.
Who should consider this trial
Good fit: Adult (≥18 years) primary kidney transplant recipients from living or deceased donors who can give informed consent and are not taking antiplatelet therapy are ideal candidates.
Not a fit: Patients on antiplatelet medications, those undergoing secondary or tertiary transplants, pediatric patients, or those unable to consent are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive blood-based marker to detect acute kidney allograft rejection earlier and potentially reduce the need for some biopsies.
How similar studies have performed: Prior observational work has linked elevated platelet activation markers to rejection, but using platelet aggregation profiles as a diagnostic tool remains preliminary and is being tested in pilot studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients (≥18 years) * primary kidney transplantation * living / deceased donor kidney transplantation * ability and consent to participate Exclusion Criteria: * non-adult patients * secondary / tertiary kidney transplantation * antiplatelet therapy * patients unable to provide informed consent
Where this trial is running
Martin
- Transplant-Nephrology Department, University Hospital Martin — Martin, Slovakia (Recruiting)
Study contacts
- Study coordinator: Timea Blichova, MD
- Email: tc@unm.sk
- Phone: +421434203184
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.